How has R&D spending in the pharmaceutical industry changed over the last decade? While the R&D collective picture for Big Pharma may not have changed much, individual company stories differ markedly.
The number of drugs in development for rare diseases have increased by 56%, with the number of rare diseases on the development map also increasing by 23% in just three years, demonstrating ongoing interest and seemingly increased enthusiasm for research within these areas of high unmet needs.
Facebook inventor Mark Zuckerberg grabbed headlines across the globe this year when he and wife Priscilla Chan announced a $3bn initiative with one momentous goal: to cure all disease. The initiative has released few details, but the pledge of $3bn from a technology business owner into disease research has sparked curiosity and concern.
Chapter sponsored by:
You must sign in to use this functionality.
Please Sign In
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with active subscriptions will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.